Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 42,544 Shares of Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) insider Ramiro Ribeiro sold 42,544 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Eyepoint Pharmaceuticals Stock Up 3.0%

Shares of EYPT opened at $17.37 on Thursday. The company has a 50-day simple moving average of $15.25 and a 200-day simple moving average of $12.89. Eyepoint Pharmaceuticals, Inc. has a 52-week low of $3.91 and a 52-week high of $19.11. The company has a market capitalization of $1.44 billion, a PE ratio of -5.81 and a beta of 1.63.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.08). The firm had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. On average, research analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its position in shares of Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock valued at $27,000 after purchasing an additional 2,733 shares during the period. State of Alaska Department of Revenue acquired a new stake in Eyepoint Pharmaceuticals during the third quarter valued at approximately $50,000. Russell Investments Group Ltd. bought a new stake in Eyepoint Pharmaceuticals in the third quarter valued at $76,000. Tower Research Capital LLC TRC increased its position in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth approximately $100,000. Institutional investors own 99.41% of the company’s stock.

Analyst Ratings Changes

EYPT has been the subject of several recent research reports. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a report on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada raised their price target on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $29.25.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.